Former SEC commissioner named chief legal officer at under-fire drugmaker

28 March 2017

Daniel Gallagher – who from November 2011 to October 2015 was Commissioner of the US Securities and Exchange Commission (SEC) – has joined Netherlands-incorporated drugmaker Mylan (Nasdaq: MYL) as the company’s chief legal officer.

Mr Gallagher joins Mylan from Patomak Global Partners, a consulting firm providing strategic advice, compliance consulting, and litigation and regulatory enforcement services, where he was president, though he may be known to a wider audience for his work with the SEC.

"I believe Mylan is uniquely positioned as a result of its clear and compelling vision and strategy, unmatched global assets, strong culture and unwavering commitment to doing what is right"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK